The complement cascade (CC) becomes activated and its cleavage fragments play a crucial role in the mobilization of hematopoietic stem/progenitor cells (HSPCs). Here, we sought to determine which major chemoattractant present in peripheral blood (PB) is responsible for the egress of HSPCs from the bone marrow (BM). We noticed that normal and mobilized plasma strongly chemoattracts HSPCs in a stromal-derived factor-1 (SDF-1)-independent manner because (i) plasma SDF-1 level does not correlate with mobilization efficiency; (ii) the chemotactic plasma gradient is not affected in the presence of AMD3100 and (iii) it is resistant to denaturation by heat. Surprisingly, the observed loss of plasma chemotactic activity after charcoal stripping suggested the involvement of bioactive lipids and we focused on sphingosine-1-phosphate (S1P), a known chemoattracant of HSPCs. We found that S1P (i) creates in plasma a continuously present gradient for BM-residing HSPCs; (ii) is at physiologically relevant concentrations a chemoattractant several magnitudes stronger than SDF-1 and (iii) its plasma level increases during mobilization due to CC activation and interaction of the membrane attack complex (MAC) with erythrocytes that are a major reservoir of S1P. We conclude and propose a new paradigm that S1P is a crucial chemoattractant for BM-residing HSPCs and that CC through MAC induces the release of S1P from erythrocytes for optimal egress/mobilization of HSPCs.
Introduction
Hematopoietic stem/progenitor cells (HSPCs) circulate in the peripheral blood (PB) under steady-state conditions at a very low level to keep a pool of stem cells in balance in the bone marrow (BM) microenvironment located in distant bones. Therefore, PB could be envisioned as a highway by which HSPCs relocate in the body between hematopoietic BM endosteal and endothelial niches. HSPCs are mobilized from the BM into PB during infection 1, 2 and tissue injury, 3, 4 and after administration of some pharmacological agents (for example, granulocyte colonystimulating factor (G-CSF) 5 or some polysaccharides (for example, zymosan) 6 ). However, the molecular mechanisms controlling the mobilization of HSPCs are still not well understood. Evidence is accumulating that the crucial role in this process involves attenuation of the stromal-derived growth factor-1 (SDF-1)-CXCR4 interaction between BM-secreted SDF-1 and HSPC-expressed CXCR4 7 and the adhesive interaction between very late antigen-4 (VLA-4; a 4 b 1 integrin) expressed on HSPCs and its ligand vascular adhesion molecule-1 (VCAM-1; CD106), which is expressed in the BM microenvironment. [8] [9] [10] [11] Increasing evidence shows also that HSPC mobilization is regulated/orchestrated by elements of innate immunity, in particular by complement cascade (CC) protein cleavage fragments 12, 13 and neutrophils, [14] [15] [16] which all play a pivotal and, until recently, underappreciated role in this process. Recently we reported that CC is activated in BM during mobilization of HSPCs and that C5 cleavage fragments direct egress of HSPCs from BM into PB mainly by promoting proteolytic activity of the BM environment and inducing BM egress of granulocytes. Granulocytes are the first cells to egress and thus pave the way for HSPCs to follow in their footsteps. 16 In this study, we sought to determine which major chemoattractant is present in PB that is responsible for egress of HSPCs and whether activation of CC has some role in its level/ expression. We observed that plasma derived from normal and mobilized PB strongly chemoattracts murine BM HSPCs and that this chemotactic effect was not dependent on plasma SDF-1 levels because (i) it occurs in the presence of the CXCR4 antagonist AMD3100; (ii) it is robust to heat-inactivated plasma and (iii) ELISA studies showed negligible concentrations of SDF-1 in plasma, which did not correlate with good or poor mobilizer status. However, the chemotactic activity of plasma was abolished after charcoal stripping which suggested involvement of bioactive lipids. On the basis of this we focused on sphingosine-1-phosphate (S1P), a known chemoattractant for HSPCs, whose major reservoir in PB is erythrocytes. 17, 18 Supporting this notion plasma isolated from mobilized mice was shown to contain traces of free hemoglobin and the level of hemolysis correlated with CC activation and generation of membrane attack complex (MAC).
On the basis of this we postulate that HSPCs are actively retained/anchored in the BM niches in for example, an SDF-1-CXCR4-and VCAM-1-VLA-4-dependent manner that counteracts the continuous influence of the S1P-mediated chemotactic gradient of plasma. During mobilization CC becomes activated and interaction of the MAC with circulating erythrocytes leads to an additional increase in plasma S1P. Thus, S1P is a crucial plasma component that chemoattracts HSPCs and directs their release from the BM niches into PB.
Materials and methods

Animals
Pathogen-free, 4-to 6-week-old C5 À/À , C5 þ / þ mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA; http://www.jax.org). C57BL/6 mice were purchased from the National Cancer Institute (Frederick, MD, USA; http://www. cancer.gov). All mice were allowed to adapt for at least 2 weeks and used for experiments at age 6-8 weeks. Animal studies were approved by the Animal Care and Use Committee of the University of Louisville (Louisville, KY, USA).
Plasma
PB samples were obtained from 16 patients. The clinical characteristics of these patients are presented in Supplementary  Table 1 . There were 11 male and 5 female patients, 8 diagnosed with non-Hodgkin lymphoma, 5 with Hodgkin's lymphoma, 2 with germ cell tumor and 1 with acute myeloblastic leukemia, who had been mobilized with chemotherapy followed by G-CSF (filgrastim 5 ml/kg BID; Amgen, Thousand Oaks, CA, USA) in accordance with the guidelines approved by the Human Ethics Research Board of the Faculty of Medicine and Dentistry at the University of Alberta (Edmonton, Canada). During mobilization CD34
þ cell and WBC counts were monitored. Patients were classified as good mobilizers when their CD34 þ cell count reached 450 cells/ml, and as poor mobilizers when it was below 50 cells/ml, on the day of leukapheresis.
Murine plasma was obtained from the vena cava (a 1 ml syringe containing 50 ml of 100 mM EDTA) from normal and AMD3100-, or zymosan-mobilized mice. Plasma samples were prepared by taking the top fraction after centrifugation at 1000 Â g for 10 min at 4 1C. The samples were stored at À80 1C until use. In some experiments we used heat-inactivated (56 1C, 30 min), boiled (10 min) or charcoal-stripped plasma prepared as described elsewhere.
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Plasma SDF-1, S1P and C5 cleavage fragment and free hemoglobin measurements Plasma SDF-1 levels were evaluated by sandwich ELISA using the commercially available ELISA system (R&D Systems, Minneapolis, MN, USA). S1P levels were analyzed using a commercially available plasma S1P detection kit (Echelon Biosciences Inc., Salt Lake City, UT, USA).
Plasma CC activation levels were analyzed by sandwich ELISA as described elsewhere. 20 Briefly, plasma samples were incubated in triplicate wells of microtiter plates, which had been pre-coated with antigen-specific capture antibodies (Abs) (C5a). Repeated washing and aspiration were conducted before each incubation step to remove unbound material from the assay plates. This step was followed by incubation with specific biotin-labeled capture Abs and an enzyme reagent. A substrate solution was added to the wells of the microtiter plates and a color developed in proportion to the amount of antigen bound in the initial step of the individual assay. Color development was stopped by addition of an acid solution and the intensity of the color was read using a microtiter plate spectrophotometer. Hemolysis levels were analyzed by measuring the absorbance of plasma at 540 nm as described elsewhere 21 and calculated as percentage of hemolysis expressed as fold increase of hemoglobin in mobilized plasma as compared with normal plasma.
Mobilization
Mobilization in mice was induced by G-CSF, zymosan or AMD3100. For G-CSF mobilization mice were injected subcutaneously with 250 mg/kg of human G-CSF (Amgen; http://www.amgen.com) daily for 6 days. For zymosan mobilization, mice were injected intravenously with 0.5 mg per mouse and for AMD3100 mobilization with a dose of 5 mg/kg subcutaneously. At 6 h after the last G-CSF administration or 1 h after zymosan or AMD3100 injection, mice were bled into microvette EDTA-coated tubes (Sarstedt Inc., Newton, NC, USA; http://www.sarstedt.com) from the retro-orbital plexus to obtain a complete blood count and 450 ml of PB was obtained from the vena cava using a 25-gauge needle and a 1 ml syringe containing 50 ml of 100 mM EDTA. Some mice were treated with deoxypyridoxin (DOP, 30 mg/l) with glucose (10 g/l) in drinking water, as described elsewhere, 22 for 14 h before BM harvest or AMD3100 administration.
Evaluation of HSPC migration and mobilization in mice
To count the number of HSPCs, we used a colony-forming assay and fluorescence-activated cell sorting analysis for Sca- 
Colony-forming assay
To evaluate the number of circulating progenitor cells after mobilization, a colony-forming cell assay was employed. RBCs were lysed with BD Pharm Lyse buffer (BD Biosciences, San Jose, CA, USA; http://www.bdbiosciences.com). Nucleated cells were subsequently washed twice and used for colony-formation assays. Briefly, cells were resuspended in methylcellulose base media provided by the manufacturer (R&D Systems Inc.; http:// www.rndsystems.com) supplemented with granulocyte macrophage colony-stimulating factor (GM-CSF, 25 ng/ml) plus interleukin-3 (10 ng/ml) for CFU-GM; G-CSF (20 ng/ml) for CFUgranulocyte (G); macrophage colony-stimulating factor (M-CSF, 10 ng/ml) for CFU macrophage (M); erythropoietin (5 U/ml; Stem Cell Tech, Vancouver, BC, Canada; http://www.stemcell.com) plus stem cell factor (5 ng/ml) for burst-forming units (BFU-E) and thrombopoietin (100 ng/ml) for CFU-megakaryocytes. All growth factors were purchased from the same company unless otherwise mentioned. Cultures were incubated for 7 days, at which time they were scored using an inverted microscope for the number of each colonies.
Fluorescence-activated cell sorting analysis
Cell staining was performed in a medium containing 2% fetal bovine serum. All monoclonal Abs were added at saturating concentrations and the cells were incubated for 30 min on ice, washed twice, resuspended in staining buffer at a concentration of 5 Â 10 6 cells/ml and subjected to analysis using an LSR II (BD, Mountain View, CA, USA). The following anti-mouse monoclonal Abs were used to detect fluorescein isothiocyanate-anti-CD117 (c-Kit) (clone 2B8; BioLegend, San Diego, CA, USA) and phycoerythrin-Cy5 anti-mouse Ly-6A/E (Sca-1) (clone D7; eBioscience, San Diego, CA, USA). All anti-mouse lineage markers (Lin) were conjugated by phycoerythrin and purchased from BD Biosciences: anti-CD45R/B220 (clone RA3-6B2); antiGr-1 (clone RB6-8C5); anti-T-cell receptor b (TCRb; clone H57-597); anti-TCRgd (clone GL3); anti-CD11b (clone M1/70); anti-Ter-119 (clone TER-119); and anti-CD34 (clone RAM34).
BM nucleated cells
BM nucleated cells (BMNCs) were prepared by flushing the femurs and tibias of pathogen-free, 6-to 8-week-old mice without enzymatic digestion. The BMNCs were lysed with BD Pharm Lyse buffer to remove RBCs, washed and resuspended in RPMI containing 0.5% bovine serum albumin. In some experiments, the BMNCs were exposed to AMD3100 (5 mM), heat-inactivated normal plasma from the same donor, or S1P for 1 h at 37 1C before use in the trans-well migration assay.
Trans-well migration assay
The trans-well migration assay was performed as described elsewhere. 16 Briefly, unless otherwise indicated, RBC-lysed BMNCs from C57BL/6 mice were resuspended in assay media (RPMI containing 0.5% bovine serum albumin) and equilibrated for 10 min at 37 1C. An assay medium (650 ml) containing test reagents was added to the lower chambers of a Costar Transwell plate (Costar Corning, Cambridge, MA, USA). Aliquots of cell suspension (1 Â 10 6 cells/100 ml) were loaded onto the upper chambers using 5 mm-pore filters, then incubated for 3 h (37 1C, 5% CO 2 ). Cells from the lower chambers were scored using fluorescence-activated cell sorting analysis for migration of BMNCs to test regents. The results are express as fold increase, that is, the ratio of the number of cells that migrated toward the test reagents to the number of cells that migrated toward the medium alone. In some experiments, migrated cells harvested from the lower chambers were plated in colonyforming assays as mentioned earlier.
MAC deposition
Immunolocalization of each MAC in femur was performed using an immunoperoxidase system. Briefly, 4-mm paraffin sections, after deparaffinization and rehydration, were treated with 0.3% hydrogen peroxide in absolute methanol for 30 min to quench endogenous peroxidase activity and incubated in 10% normal goat serum for 60 min to block non-specific binding. Following overnight incubation with rabbit anti-murine C5b-9 Ab (1:100; Abcam, Cambridge, MA, USA; no. ab55811), the sections were exposed to horseradish peroxidase-conjugated goat-anti rabbit IgG (1:1000; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) for 60 min. Immunoreactivity was visualized using a liquid diaminobenzidine Substrate Chromogen System (Sigma-Aldrich Co., St Louis, MO, USA). The sections were rinsed thoroughly in tap water, lightly counterstained with hematoxylin, dehydrated through graded ethanol, cleared in xylene and mounted using a mounting media.
Statistical analysis
Arithmetic means and standard deviations were calculated using the Instat 1.14 software (GraphPad, San Diego, CA, USA). Statistical significance was defined as Po0.05. Data were analyzed using Student's t-test for unpaired samples.
Results
Plasma SDF-1 level does not correlate with the mobilization efficiency of HSPCs
Our first aim was to determine whether SDF-1 plasma level correlates with the efficiency of mobilization of CD34 þ cells; hence we used ELISA to measure the SDF-1 level in the plasma obtained from 16 patients (classified as good and poor mobilizers). We found that plasma SDF-1 concentration was about 600 pg/ml and that it does not increase during G-CSFinduced mobilization. Moreover, both good (n ¼ 9) and poor (n ¼ 7) mobilizers had similarly low levels of SDF-1 ( Figure 1a and Supplementary Table I) .
As observed in patients' plasma, SDF-1 level was also very low in murine plasma and did not increase significantly after G-CSF-or zymosan-induced mobilization (Figure 1b) . Of note, but as expected and shown in Figure 1c , this low physiological concentration of SDF-1 (B2 ng/ml) does not have significant chemotactic activity against murine CFU-GM.
HSPCs egress from the BM into PB in an SDF-1-independent manner
To identify factor/s responsible for chemoattraction/egress of HSPCs from the BM into PB, we evaluated the chemotactic activity of normal murine and human plasma (Figure 2 and Supplementary Figure 1) . Figure 2a shows that murine CFU-GM are chemoattracted by murine plasma much stronger than by plasma physiological SDF-1 level (1-2 ng/ml). Potential involvement of SDF-1 in plasma chemotaxis was excluded by showing that AMD3100-treated murine CFU-GM responded to a plasma gradient and that this chemotactic response was not affected by heat inactivation (Figure 2a) . Interestingly, as is shown in Figure 2b , removal of lipids from plasma by charcoal stripping abrogated plasma chemotactic activity but did not affect the chemotactic responsiveness to SDF-1 (50 ng/ml) that was added to the plasma before charcoal stripping. This suggests an involvement of lipid components in the observed plasma chemotactic activity. Overall both murine and human 2-5% plasma (Figure 2 and Supplementary Figure  1A and B) chemoattract BM-derived CFU-GM; however, this chemotactic effect decreased with higher plasma concentration.
S1P level in PB increases during mobilization
S1P is a bioactive lipid that was reported to chemoattract HSPCs. 23 Thus, we measured S1P level in murine plasma during mobilization and found that it increases 2-4 times depending on the mobilization agent used (Figure 3a) . We noticed that although S1P did not chemoattract BMNCs (Figure 3b) it strongly chemoattracted the BM-residing CFU-GM (Figure 3c ) as well as other clonogeneic progenitors (Supplementary Figure  2) . This effect seems to be specific for BM-residing naïve CFU-GM, but was significantly weaker for the CFU-GM circulating in PB (Figure 3d ). In control experiments, blood-isolated CFU-GM also showed weaker chemotactic response to SDF-1 as compared with the BM naïve counterparts. We also noticed in our chemotactic assays that the responsiveness of the BMderived CFU-GM is S1P dose-dependent and shows a bellshaped curve, being most optimal at dose B100 nM and decreasing with higher S1P concentrations (Supplementary Figure 1C) . This bell-shaped curve for S1P chemotactic responsiveness corresponds to chemotactic activity in murine and human plasma (Supplementary Figure 1A and B) , which also shows a bell-shaped curve.
To further explore the involvement of S1P, we evaluated the chemotactic responsiveness of the BM-isolated CFU-GM that were exposed to plasma (Figure 4a ) or pre-incubated with S1P before the chemotactic assay (Figure 4b ). Both pre-incubation of BM-derived CFU-GM with plasma and S1P inhibited their chemotactic responsiveness to S1P but not to SDF-1 (Figures 4a  and b ). This indicates that the chemotactic responsiveness to S1P may be affected/desensitized by previous exposure to this bioactive lipid.
S1P is released during mobilization form erythrocytes in an MAC-dependent manner
Erythrocytes are a major source/reservoir of S1P in PB. 17, 18 On the basis of our data that the later steps of CC activation are crucial for egress of HSPCs from the BM into PB 16, 20 we tested the possibility that the final product of CC activation, MAC, could be involved in the release of S1P from erythrocytes. Figure 5a shows that activation of the later steps of CC activation as evaluated by C5a ELISA correlates with the plasma free hemoglobin level. The generation of MAC deposits in the BM of mobilized wild-type mice and lack of these deposits in C5 À/À mice that do not activate the later steps of CC and do not generate MAC was confirmed by immunohistochemical staining (Figure 5b ). Figure 5c shows that murine CFU-GM show the bell-shaped curve in chemotactic responsiveness to erythrocyte lysates.
DOP-treated mice are poor mobilizers
It has been reported that activity of enzyme that degrades S1P (S1P lyase) depends on vitamin B6 that serves as a co-enzyme, and DOP, a vitamin B6 antagonist, decreases its activity in tissues. 22 Therefore, to better investigate the role of S1P in the release of HSPCs from the BM we treated mice with DOP and subsequently evaluated the chemotactic response of the BM CFU-GM from control and DOP-treated mice to S1P. Figure 6a shows that the CFU-GM cells from DOP-treated BM, which were exposed in the BM environment to a high level of S1P (due to lack of S1P lyase activity), do not respond to an S1P gradient. Furthermore, we also noticed that DOP-treated mice became poor mobilizers (Figures 6 b-d) . Again this could be explained by desensitization of their responsiveness to an S1P gradient after exposure to the high concentration of S1P that accumulates in the BM due to lack of S1P lyase activity. Figure 2 HSPCs egress from the BM into PB in an SDF-1-independent manner. (a) Murine CFU-GM are much more efficiently chemoattracted by murine plasma than by a physiological concentration of SDF-1. Potential involvement of SDF-1 can be excluded because normal CFU-GM progenitor cells (black bar) responded to heat-inactivated plasma (HI-P) as well as in presence of 5 mM AMD3100 (white barFnormal plasma (NP)). However, exposure to AMD3100 inhibited chemotaxis to SDF-1. (b) CFU-GM cells do not migrate to charcoal-stripped, lipid-free plasma; however, they respond normally to the SDF-1 added (50 ng/ml) charcoal-stripped plasma. M, media-alone control; NP, normal murine plasma (2.5%); HI-P, heat-inactivated murine plasma (2.5%); SDF-1 (ng/ml); FP, filtered normal plasma filtered with a 0.22-mm membrane; FP-LF, charcoal-stripped and filtered plasma. *Po0.01. The data shown are the combined results from three independent experiments carried out in triplicate per group (n ¼ 9). BM, bone marrow; CFU-GM, granulocyte/macrophage colony-forming units; HSPC, hematopoietic stem/progenitor cell; PB, peripheral blood; SDF, stromal-derived factor-1.
Discussion
The process of HSPC mobilization is still not fully understood and a significant number of patients, particularly those with previous history of chemotherapy, are poor mobilizers. 24, 25 Several BM microenvironment-related factors have been identified that regulate mobilization, including (i) release of proteases by activated myeloid cells, which perturb the SDF-CXCR4, VLA-4-VCAM-1 interactions, 9,10 and the KL-c-KitR axes; 26 (ii) release of neurotransmitters by neural fibers that innervate BM tissue; 27 (iii) downregulation of SDF-1 mRNA expression in the osteoblastic stem cell niche; 28, 29 (iv) activation of osteoclasts 30 and (v) upregulation of the serpin-family protease inhibitors. Figure 4 S1P-exposed or plasma-pre-incubated BM-HSPCs do not respond to S1P. Pre-incubation of BM HSPCs with plasma from the same donor (a, striped bar) or with S1P (b) (gray bar (100 nM); white bar (500 nM)) for 1 h abrogated the migration of BM-naïve CFU-GM progenitors to an S1P gradient. M, media-alone control. *Po0.001. The data shown represent the combined results from three independent experiments performed in triplicate per group (n ¼ 9). BM, bone marrow; CFU-GM, granulocyte/macrophage colony-forming units; HSPC, hematopoietic stem/progenitor cell.
We reported CC is activated in the BM during mobilization of HSPCs and that CC cleavage fragments direct the egress of HSPCs into PB by modulating the activity of granulocytes. 16 Supporting this notion was our finding that mice that do not efficiently activate the later steps of CC are poor mobilizers 13, 16, 20 and, as reported by several groups, mobilization of HSPCs is severely reduced in neutropenic mice. 33, 34 It has been also shown that granulocytes are a major source of proteolytic enzymes in the BM that perturb HSPC retention signals and are the first cells to egress from the BM. 16 To clarify the role of the later CC activation steps and granulocytes we showed that C5 cleavage fragments affect several important neutrophil-mediated steps of HSPC mobilization. First, they may increase the secretion of proteases by BMresiding granulocytes and their precursors, which leads to enzymatic disintegration of HSPC anchorage signals in the BM niches. Second, C5 cleavage fragments along with interleukin-8, NAP-2, growth-related oncogene protein-b create in plasma a chemotactic gradient for C5aR þ granulocytes and promote their egress into PB. Granulocytes, being highly enriched in proteolytic enzymes, are crucial for 'permeabilization' of the BM-blood barrier and thus these cells pave the way for HSPCs expressing proteolytic enzymes at a low level to follow in their footsteps.
G-CSF is currently the most frequently used mobilizing agent that efficiently mobilizes HSPCs after a few consecutive daily injections. Mobilization can also be induced within hours after administration of certain chemokines (for example, interleukin-8, 32 growth-related oncogene protein-b, 34 macrophage inhibitory protein-1a (MIP-1a) 35 or small molecular CXCR4 receptor, for example, AMD3100, and VLA-4, for example, BIO5192, antagonists 36 ). Additionally, in experimental animals, mobilization also occurs within 1 h after a single injection of some polysaccharides (for example, zymosan, fucoidans). 37 It has been envisioned that HSPCs released from their hematopoietic niches egress from the BM into PB in response to increasing plasma SDF-1 levels. 5, 6, 38, 39 However, the role of plasma SDF-1 level in the egress of HSPCs is not clear. 40 We report here that plasma derived from normal and mobilized PB strongly chemoattracts murine HSPCs. More important, this chemotactic effect is not dependent on the concentration of SDF-1 because (i) it occurs in the presence of the CXCR4 antagonist AMD3100; (ii) it is robust to heat-inactivated plasma and (iii) ELISA studies show negligible concentrations of SDF-1 in plasma, which did not correlate with good or poor mobilizer status. This last observation is in agreement with a recent report indicating that plasma SDF-1 levels do not correlate with G-CSF-induced mobilization efficiency in patients. 41 However, as reported, some priming factors released during mobilization such as complement cascade protein C3 cleavage fragments (C3a and desArgC3a), as well as cathelicidin released from activated granulocytes, could enhance the responsiveness of HSPCs to SDF-1; 2,16 nevertheless, this priming phenomenon does not explain the remarkable chemotactic potential of plasma. On the basis of this, we sought to determine which major chemoattractant present in PB that is responsible for the egress of HSPCs and whether activation of the later steps of CC has some role in its level.
We found that the chemotactic activity of plasma was almost completely abolished after charcoal stripping, suggesting the involvement of a bioactive lipid. As we detected free hemoglobin in the plasma of mobilized animals, we explored the possibility that the MAC generated during the activation of the last step of CC could affect erythrocytes, which release some chemotactic factor/s. In support of this we found that erythrocyte lysates indeed exert a strong chemotactic effect on HSPCs, which is in agreement with observations that HSPCs are robustly mobilized during intravascular lysis of erythrocytes, for example, in sickle cell crisis. 42 It is well known that erythrocytes are stored in blood and release S1P, 17, 18 , a bioactive lipid that has been reported to posses chemotactic activity against HSPCs as well as regulate the egress of lymphocytes into the blood and lymph. 43, 44 Of note, S1P is the only known chemoattractant for HSPCs besides SDF-1 and has been postulated to have a role in CD34 þ cell homing to the BM. The pro-homing/chemotactic effects of S1P are mediated by five G-protein-coupled seven-transmembrane span receptors (S1P1-S1P5). 45, 46 While binding of S1P to S1P1 receptor promotes the chemotaxis of CD34 þ cells, 23 activation of the S1P2 receptor has an opposite effect. 47 In addition, binding of S1P to S1P3 increases CXCR4 receptor signaling and enhances the responsiveness of HSPCs to an SDF-1 gradient. 48 In this work we provide evidence that S1P is a major chemotactic component of normal plasma that directs the egress of HSPCs into PB. We show that S1P is already present in the plasma under normal steady-state conditions and creates a gradient continuously chemoattracting BM-residing HSPCs. To counteract this S1P egress gradient HSPCs are actively retained in the BM through SDF-1-CXCR4 and VLA-4-VCAM-1 interactions. Therefore, perturbation of these interactions by (i) creating a proteolytic microenvironment that affects retention signals, or (ii) directly blocking the CXCR4 of VLA-4 by small-molecule antagonists (for example, AMD 3100 or BIO5192, respectively) is sufficient to shift a BM-retention balance toward a plasma S1P gradient that directs the egress of HSPCs into PB. Furthermore, as we showed, as during mobilization CC is activated and an MAC is generated, this leads to additional increases in plasma S1P released from erythrocytes. It is known that erythrocytes are highly protected from the MAC by CD59 and decayaccelerating factor receptors (which are lacking on erythrocytes in paroxysmal nocturnal hemoglobineuria patients, a disorder characterized by erythrocyte lysis). 49 .However, expression of these receptors on erythrocytes does not give complete protection from activated MAC. Our data support the notion that erythrocytes form a buffer system that controls S1P levels in PB and release of S1P from erythrocytes as seen during hemolysis, 42, 49 or, as shown here, after mobilization induced MAC exposure increase the free levels of S1P that regulate the BM-egress of HSPCs.
Our data also indicate that the chemotactic responsiveness of HSPCs to S1P depends on S1P level and source of cells. Accordingly, S1P that strongly chemoattracts HSPCs at doses of 100-500 nM inhibits their chemoattraction in higher concentrations. It is possible that higher doses of S1P promote signaling through the S1P2 receptor, which in contrast to S1P provides chemotactic inhibitory signals. This explains why we observed optimal chemotaxis of HSPCs to diluted murine and human plasma, and its inhibition in the presence of higher plasma concentrations. Moreover, while naïve BM-derived CFU-GM showed robust chemotaxis to S1P, this effect was not evident for CFU-GM already mobilized and circulating in PB or for BMderived CFU-GM exposed to S1P or pre-incubated with plasma. We observed a similar effect for HSPCs from DOP-treated animals that express high levels of S1P in the BM microenvironment. These data could be explained by desensitization of cell responsiveness due to S1P1 downregulation after exposure to S1P. 47, 50 Interestingly, whereas S1P strongly chemoattracts HSPCs it does not affect the migration of granulocytes. Therefore, optimal HSPC mobilization depends on the activation of the later steps of CC and the generation of C5 cleavage fragments that induce the egress of granulocytes. On the basis of this, C5 cleavage fragments and S1P together orchestrate the egress of HSPCs by inducing the BM egress of granulocytes that pave the way for HSPCs (C5 cleavage fragments), and by the direct chemoattraction by S1P of HSPCs that follow the granulocytes.
On the basis of these data, we propose the following scenario ( Figure 7 ). Under the steady-state condition, HSPCs are retained in the BM due to active SDF-1-CXCR4/VLA-4-VCAM1 interactions that counteract the continuous chemotactic S1P gradient present in PB. To induce mobilization, a mobilizing agent (for example, G-CSF) activates the CC in the BM, which subsequently increases the release of proteolytic enzymes from granulocytes, which in turn perturb the SDF-1-CXCR4/ VLA-4-VCAM1 interactions or simply block these axes (for example, AMD3100 or BIO5192, respectively) (Step-I). The mobilization process subsequently activates the CC and the later steps of this cascade are required for optimal egress of HSPCs. Accordingly, C5 cleavage fragments promote the egress of granulocytes that pave the way for the egress of HSPCs (Step-II). These observations made in mice 16 were recently confirmed in patients. 51 Simultaneously, concentration of S1P in plasma increases due to release of S1P from erythrocytes in an MACdependent manner, providing a more optimal gradient for HSPCs. Thus S1P accumulation in BM sinusoids along with C5 cleavage fragments, but not changes in plasma SDF-1 levels, are crucial executors of HSPC egress from the BM into PB (Step-III).
However, further studies are needed to confirm a role of S1P in egress of HSPCs in mobilized patients as well as to evaluate involvement of other bioactive lipids that in addition to S1P could play a role in mobilization of HSPCs.
